MDS Abstracts

Abstracts from the International Congress of Parkinson’s and Movement Disorders.

MENU 
  • Home
  • Meetings Archive
    • 2024 International Congress
    • 2023 International Congress
    • 2022 International Congress
    • MDS Virtual Congress 2021
    • MDS Virtual Congress 2020
    • 2019 International Congress
    • 2018 International Congress
    • 2017 International Congress
    • 2016 International Congress
  • Keyword Index
  • Resources
  • Advanced Search

Quantitative gait analysis to evaluate changes in gait pattern after Botulinum toxin A injection by hemiparesis

M. Pinter, M. Petrovicsova, Y. Teuschl, A. Dachenhausen, K. Matz, C. Bancher (Krems, Austria)

Meeting: 2023 International Congress

Abstract Number: 947

Keywords: Botulinum toxin: Clinical applications: spasticity, Gait disorders: Treatment, Spasticity: Treatment

Category: Spasticity

Objective: This retrospective study aimed to assess the effect of Botulinum toxin A (BoNT-A) injections in the lower limbs of hemiparetic patients on gait parameters, and to explore the relationship between improvements in clinical assessments and kinematic / spatiotemporal parameters assessed by gait analysis.

Background: BoNT-A is an effective treatment for spasticity. Apart from improving muscle tonus and range of motion in specific joints, injections in the lower limbs of hemiparetic patients improved subjective scales and clinical assessments of walking speed. Data on the effect of BoNT-A on functional outcomes described by spatiotemporal parameters and kinematics are rare.

Method: Hemiparetic patients with focal spasticity, admitted at a neurorehabilitation clinic from 2018 to 2021, injected with BoNT-A in the lower limbs, and with two gait analysis available (the first near the date of injection and the second 10 or more days after the injection) were included in this retrospective analysis.

Results: Data of 3 women and 6 men, mean age 50 years, with hemiparesis (5 right, 4 left) were analyzed. In total, a mean of 261.1 mouse units ± 49.6 SD of BoNT-A was injected in the affected lower extremity. After the injection, the distance walked during the 4 minutes timed walk test (TWT) had significantly improved from in median 130m (quartiles: 110; 246) to 185m (102; 263) and the walking performance had significantly improved on a subjective scale (range 1 to 10) from 6 (6; 8) to 9 (7; 10). In the gait analysis, significant improvements were only found for the pre-swing phase of the affected leg, which decreased from 24.7% (19.8%; 31.2%) to 23.4% (19.9%; 28.1%). Improvements in the TWT were correlated with improvements in the cadence during gait analysis (Spearman rho [rs] 0.790, p=0.011). Furthermore, it correlated with parameters of the first gait analysis: Persons with shorter double stance phase (rs -0.678, p=0.045), longer single stance phase (rs 0.728, p=0.026) and shorter loading response (rs -0.845, p=0.004) on the affected side, as well as shorter stance phase (rs -0.711, p=0.032) and shorter pre-swing phase (rs -0.853, p=0.003) on the non-affected side improved more on the TWT.

Conclusion: Persons with more symmetrical kinematic gait measures before BoNT-A injections had the largest improvements in the TWT.

To cite this abstract in AMA style:

M. Pinter, M. Petrovicsova, Y. Teuschl, A. Dachenhausen, K. Matz, C. Bancher. Quantitative gait analysis to evaluate changes in gait pattern after Botulinum toxin A injection by hemiparesis [abstract]. Mov Disord. 2023; 38 (suppl 1). https://www.mdsabstracts.org/abstract/quantitative-gait-analysis-to-evaluate-changes-in-gait-pattern-after-botulinum-toxin-a-injection-by-hemiparesis/. Accessed June 14, 2025.
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2023 International Congress

MDS Abstracts - https://www.mdsabstracts.org/abstract/quantitative-gait-analysis-to-evaluate-changes-in-gait-pattern-after-botulinum-toxin-a-injection-by-hemiparesis/

Most Viewed Abstracts

  • This Week
  • This Month
  • All Time
  • Humor processing is affected by Parkinson’s disease and levodopa
      • Help & Support
      • About Us
      • Cookies & Privacy
      • Wiley Job Network
      • Terms & Conditions
      • Advertisers & Agents
      Copyright © 2025 International Parkinson and Movement Disorder Society. All Rights Reserved.
      Wiley